Genoskin Launches VaxSkin®: A Service Offering to Advance Vaccine Development

Oct 17, 2023

Innovative Service Utilizes Human Skin to Deliver Crucial Data Ahead of Clinical Trials, Enhancing Vaccine Research and Development

Posted by Genoskin

Toulouse, France, and Salem, MA, US, October 16th, 2023 – 

Genoskin, a biotechnology company that leverages live ex vivo human skin to test therapeutic and non-therapeutic products, today announces the launch of its new service, VaxSkin®. This unique service is poised to transform vaccine development by identifying key immune responses and delivering essential data in the early stages, ahead of clinical trials.

VaxSkin® is powered by the innovative HypoSkin® technology, which combines bio-stabilized, immunocompetent ex vivo human skin with multiomic assays and computational molecular pathway analysis. This holistic approach offers a wealth of insights into human immune responses to vaccine injection, enabling researchers to advance their studies with precision and confidence.


Key Features of VaxSkin® Include:


  • Human-Centric Data: VaxSkin® provides invaluable human-centric data prior to initiating  clinical trials, ensuring more accurate and reliable data.

  • Comprehensive Testing: Customers can test various vaccine formulations and doses  using a single donor, optimizing the research process.

  • Diverse Human Responses: VaxSkin® mimics responses in diverse human populations, ensuring a comprehensive understanding of the vaccine’s impact.

  • Advanced Technologies: Incorporates multiplex cytokine release assays, bulk RNA sequencing, single-cell RNA sequencing, and MANTIS® multiplex spatial imaging.

About Genoskin

Genoskin stands at the forefront of transformative non-clinical platforms, specializing in leveraging human skin to test therapeutic and non-therapeutic products. Founded in 2011 as a spin-off of the French National Center for Scientific Research (CNRS) and The Paul Sabatier University in Toulouse, Genoskin has been steadfast in its commitment to providing a reliable alternative to animal-based experiments. Utilizing real human tissues ethically sourced from plastic surgeries and cutting-edge technologies, Genoskin ensures the viability, immunocompetency, and functionality of human skin samples, promoting safer and more effective drug development.

VaxSkin® is a testament to Genoskin’s unwavering dedication to innovation and excellence in the realm of non-clinical testing and vaccine development. For more information about VaxSkin® and Genoskin’s transformative services, please visit our website.


Media Contact:

Lorna Santos, VP of Marketing and Product Management

See all Member News